Contents:

EXECUTIVE SUMMARY Scope Datamonitor insight into the ovarian cancer market With the impending genericization of carboplatin and paclitaxel, which currently dominate the pharmacological treatment of ovarian cancer, and the lack of products that stand out from the rest of the pipeline, strategic marketing and product differentiation will hold the key to commercial success. The ovarian cancer pipeline is currently dominated by a variety of agents that, by large, are being developed for multiple indications, which spreads valuable resources, and thereby limits commercial potential. Datamonitor believes that significant commercial reward is available for future pipeline products that focus efforts within the ovarian cancer therapeutic area. Cytotoxic agents have historically formed the cornerstone of the drug-based treatment of ovarian cancer. If future classes are to replace their dominance, properly controlled clinical trials and educational campaigns are a prerequisite to change physician outlook, and hence the future management of ovarian cancer. In view of future improvements in screening, and subsequent increases in early stage diagnoses, there are significant opportunities for highly specific innovative therapies, which target recurrent disease. Key metrics TABLE OF CONTENTS DISEASE OVERVIEW Definition of disease Risk factors Classification of disease Disease staging and treatment Classification of pipeline products Gold Standard Cytotoxics Immunotherapies Therapy enhancers Anti-angiogenesis agents Others Clinical endpoints in disease Disease stabilisation Quality-of-life CA 125 stabilisation Immune response Unmet needs in disease Platin resistant tumors Second-line treatments Side effects PIPELINE ANALYSIS Pipeline analysis by development strategy Key drug discovery strategies in ovarian cancer Key R&D protocol strategies in ovarian cancer Key drug delivery strategies in ovarian cancer Key licensing strategies in ovarian cancer Pipeline analysis by class Ovarian cancer pipeline analysis by region Pipeline analysis by company type DRUG ANALYSIS Cytotoxics ZD0473 Gemzar Rubitecan ILX-295501 XR5000 MGI 114 Taxotere DX8951f Immunotherapies OvaRex Theragyn O-Vax CEA-Cide Therapy enhancers Valspodar Incel XR9576 Anti-angiogenesis Thalidomide Others CP-358,774 (OSI-774) ISIS 3521 Cetrorelix Dexemel Key phase I development projects Taxosomes MetXia-P450 tgDCC-E1A Recently discontinued projects Marimastat COMPARATIVE ANALYSIS Comparison by class Efficacy Toxicity Platinum resistant tumors Comparative analysis of cytotoxics Comparison of satisfaction of unmet needs within the cytotoxic class Comparative analysis of immunotherapies Comparison of satisfaction of unmet needs within the immunotherapy class Comparative analysis of angiogenesis inhibitors Comparison of satisfaction of unmet needs within the angiogenesis inhibitor class Comparative analysis of gene therapies Comparison of satisfaction of unmet needs within the gene therapy class Comparative analysis of therapy enhancers Comparison of satisfaction of unmet needs within the therapy enhancer class FUTURE FOCUS Market drivers in ovarian cancer Patent expiries New drug classes: angiogenesis inhibitors and gene therapies Price cuts in Japan Reformation of Medicare Factors affecting individual classes, 2001-2007 Future trends in the prevalence of ovarian cancer Prospective drug launches in ovarian cancer Launch forecast methodology Forecast launches in ovarian cancer from 2000 to 2007 Ovarian cancer market forecasts Forecast methodology Key R&D product forecasts Cytotoxic product forecasts Immunotherapy product forecasts Therapy Enhancer product forecasts Other product forecasts APPENDIX Research program methodology SPRINT databases SPRINT R&D; Primary Research Quantification of Data Reliability Strategic Issues and Opinion Surveys Forecasting methodology Forecasting drug launches for drugs in development in ovarian cancer Global highest stage of development Reclassification of development phases